Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.07.19.21260559: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Detailed eligibility criteria, human subjects protection, and written consent have been reported previously17 and are given in the supplementary appendix. Sex as a biological variable not detected. Randomization Design and Treatments: As previously described, this randomized placebo controlled study compared bamlanivimab (7000mg) with placebo, administered as a single intravenous infusion over a 1-hour period12,17. Blinding All other site personnel, and study participants, were blinded to treatment assignment. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Plasma samples collected at study entry and at days 1, 3 and 5 were used to measure anti-spike receptor … SciScore for 10.1101/2021.07.19.21260559: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Detailed eligibility criteria, human subjects protection, and written consent have been reported previously17 and are given in the supplementary appendix. Sex as a biological variable not detected. Randomization Design and Treatments: As previously described, this randomized placebo controlled study compared bamlanivimab (7000mg) with placebo, administered as a single intravenous infusion over a 1-hour period12,17. Blinding All other site personnel, and study participants, were blinded to treatment assignment. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Plasma samples collected at study entry and at days 1, 3 and 5 were used to measure anti-spike receptor binding domain (RBD) neutralizing antibodies (nAbs) in a surrogate viral neutralization test, and anti-nucleocapsid (anti-N) binding antibody levels. anti-spike receptor binding domain (RBD) neutralizing antibodiessuggested: Noneanti-nucleocapsidsuggested: Noneanti-Nsuggested: NoneSoftware and Algorithms Sentences Resources Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and R version 4.0 (R Foundation for Statistical Computing)18. SAS Institutesuggested: (Statistical Analysis System, RRID:SCR_008567)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04501978 Recruiting ACTIV-3: Therapeutics for Inpatients With COVID-19 Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
